DLRC Launches HTA Support to Accelerate Market Access

DLRC, an award-winning global regulatory affairs consultancy that supports the development and licensing of pharmaceutical, biotech, advanced therapy, and medtech products worldwide, launches its new Regulatory-Aligned HTA & Access Support service.

This strategic offering is designed to help biopharma, biotech, and medtech innovators navigate the complexities of EU health technology assessment (HTA), unlock reimbursement potential, and accelerate patient access across global markets.

With increasing pressure on life sciences companies to demonstrate both clinical and economic value, DLRC’s new service bridges the gap between regulatory approval and commercial success. The offering provides end-to-end HTA & Access support, from early strategy and evidence generation to submission preparation and stakeholder engagement, ensuring that every development decision supports both regulatory compliance and market access.

Key features of the Regulatory-Aligned HTA & Access Support service include:

HTA Strategy & Access Planning: Aligning evidence generation with regulatory timelines and payer expectations.
Evidence Generation Consulting: Designing studies that deliver maximum impact for coverage and pricing.
HTA Submission Preparation: Crafting compelling, scientifically rigorous dossiers for global HTA bodies.
Stakeholder Engagement: Facilitating productive dialogue with payers, HTA bodies, and clinical experts.
Market Access Intelligence: Monitoring policy shifts and competitive landscapes to inform strategy.

DLRC’s approach is insight-led and outcome-focused. It helps clients maximise the return on research investment, reduce the time to reimbursement, and transform clinical data into compelling value stories. Discover more about the new service offering here.

Hear from DLRC’s HTA and Market Access Expert, Majed Elhewaihi

“To ensure rapid access to innovative technology, the EU and UK have adopted new regulations. The EU-JCA and UK NHS 10-Year-Health Plan are key milestones. While most HTA Consultants focus on either regulatory or commercial outcomes. DLRC delivers both. Our integrated teams and dual success metrics ensure that our clients not only gain approval but also achieve optimal reimbursement and pricing outcomes.”

About DLRC

Advancing Global Patient Healthcare Through Regulatory Excellence

DLRC provides global life science companies with a wide range of regulatory affairs consulting services. DLRC is an award-winning consultancy of more than 80 highly qualified, experienced regulatory professionals and support functions operating from offices in the UK, Germany, and the US. Demonstrating a deep commitment to excellence, the team helps clients navigate the complex regulatory landscape of the life science industry by developing and executing innovative regulatory strategies, and by providing comprehensive support from early development to post-licensing activities for medicinal products and medical devices. DLRC’s regulatory team includes consultant experts in nonclinical, CMC, clinical and MedTech from pharmaceutical, medical device and regulatory agency backgrounds. DLRC has proudly served companies of all sizes and backgrounds in various regulatory jurisdictions.